


# MD Anderson at the 2025 ASCO Annual Meeting

[MDAnderson.org/ASCO](https://MDAnderson.org/ASCO)

All times are listed in Central Time.

THE UNIVERSITY OF TEXAS  
**MDAnderson**  
~~Cancer~~ Center  
Making Cancer History®



Friday, May 30			As of May 27
1:00-2:15 p.m.	Education Session	Addressing Financial Toxicity in Breast Cancer Care: Strategies for Mitigation and Support	Hall D2   Live Stream
1:24-1:36 p.m.	When the Patient Has to Take the Burden: Communication and Mitigation Strategies and Support Resources		Fumiko Chino, M.D.
1:48-2:15 p.m.	Panel Question and Answer		
1-2:30 p.m.	Rapid Oral Abstract Session	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant	E450a   On Demand
1:30-1:36 p.m.	Abstract 6512: Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)–naive patients (pts) with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial.		Guillermo Garcia-Manero, M.D.
1:36-1:42 p.m.	Abstract 6513: Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study.		Naval Daver, M.D.
1:48-2 p.m.	Panel Question and Answer		Guillermo Garcia-Manero, M.D. Naval Daver, M.D.
1-4 p.m.	Oral Abstract Session	Quality Care/Health Services Research	S504   Live Stream
2:12-2:24 p.m.	Abstract 11004: Empowering young-onset colorectal cancer patients with an accessible, self-navigable online platform for universal germline testing.		Julie Moskowitz
2:48-3 p.m.	Panel Question and Answer		
2:45-5:45 p.m.	Oral Abstract Session	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	Hall D1   Live Stream
3:45-3:57 p.m.	Chair		Timothy Yap, M.B.B.S., Ph.D.
4:33-4:45 p.m.	Panel Question and Answer Moderator		
5:33-5:45 p.m.			
2:45-5:45 p.m.	Oral Abstract Session	Central Nervous System Tumors	S100bc   Live Stream
3:45-3:57 p.m.	Chair		Nazanin Majd, M.D.
4:33-4:45 p.m.	Panel Question and Answer Moderator		
5:33-5:45 p.m.			
4:30-5:30 p.m.	Education Session	Pelvic Sarcomas: Treatment Challenges and Outcomes	S402   On Demand
4:30-5:10 p.m.	Chair/Moderator		Najat Daw, M.D.

5:10-5:30 p.m.	Panel Question and Answer Moderator		
<b>Saturday, May 31</b>			
8-9:30 a.m.	Rapid Oral Abstract Session Chair	Prevention, Risk Reduction, and Genetics	E350   On Demand
8:18-8:30 a.m.	Panel Question and Answer Moderator		Eduardo Vilar-Sanchez, M.D., Ph.D.
8:48-9 a.m.			
9:18-9:30 a.m.			
8-9:30 a.m.	Rapid Oral Abstract Session	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	E450a   On Demand
9:12-9:18 a.m.	Abstract 7017: Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study.		Michael Wang, M.D.
9:18-9:30 a.m.	Panel Question and Answer		
9 a.m.-12 p.m.	Poster Sessions	Central Nervous System Tumors Gastrointestinal Cancer—Colorectal and Anal Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Sarcoma	Hall A   On Demand
<b>See the full listing of posters from MD Anderson starting on page 9.</b>			
10-10:30 a.m.	<b>Meet the Experts: Revealing the risk: Insights on hereditary cancers</b> Banu Arun, M.D., Abenaa Brewster, M.D., and Julie Moskowitz		MD Anderson Booth 10059
11-11:30 a.m.	<b>Meet the Experts: A new era for pediatric cancer clinical trials</b> Najat Daw, M.D., and Michael Roth, M.D.		
	<b>Meet the Experts: Partnering with health systems to eliminate cancer</b> Michael Overman, M.D., and Naveen Pemmaraju, M.D., joined by Daniel Johnson, M.D., of Ochsner MD Anderson Cancer Center, Helen Ross, M.D., of RUSH MD Anderson Cancer Center, Matthew Ulrickson, M.D., of Banner MD Anderson Cancer Center and Lei Zheng, M.D., Ph.D., of UT Health San Antonio MD Anderson Cancer Center		
11:30 a.m.-12 p.m.	<b>Meet the Experts: Rare cancers: Defining the gold standard of care, Part I</b> Naveen Pemmaraju, M.D.		
	<b>Meet the Experts: Innovations in breast cancer treatment</b> Fumiko Chino, M.D.		
12:30-1 p.m.	<b>Meet the Experts: Partnering with health systems to eliminate cancer</b> Christopher Flowers, M.D., and Jennifer Litton, M.D.		
	<b>Meet the Experts: Spotlight on sarcoma</b> Ryan Denu, M.D., Ph.D.; Elise Nassif Haddad, M.D., Ph.D., and Vinod Ravi, M.D.		
1-1:30 p.m.	<b>Meet the Experts: MD Anderson's approach to whole-patient care</b> Ryan Huey, M.D., and Terri Woodard, M.D.		
1:15-2:30 p.m.	Education Session Chair	The Microbiome's Influence on Cancer Therapy: Insights and Innovations	Hall D2   Live Stream
1:30-1:45 p.m.	Designing Microbiome-Focused Clinical Trials in Cancer Immunotherapy		Jennifer McQuade, M.D.
2:00-2:30 p.m.	Panel Question and Answer Moderator		
1:15-2:15 p.m.	Case-Based Panel	Esophageal Cancer: Current Standards in an Ever-Changing Treatment Landscape	Hall D1   Live Stream
	Radiation Oncologist Perspective		Steven Lin, M.D., Ph.D.

1:55-2:15 p.m.	Panel Question and Answer		
1:15-2:30 p.m.	Education Session	ASCO/AACR Joint Session: Lessons From Gene Therapy in Practice: Successes, Challenges, and How to Have Access for All	E450a   On Demand
1:55-2:07 p.m.	Beyond CAR-T and CRISPR: What's on the Horizon?		Katy Rezvani, M.D.
2:07-2:30 p.m.	Panel Question and Answer		
1:15-4:15 p.m.	Oral Abstract Session	Breast Cancer—Metastatic	Hall B1   Live Stream
	Chair		
1:51-2:07 p.m.	Panel Question and Answer Moderator		Sharon Giordano, M.D.
2:55-3:11 p.m.			
3:59-4:15 p.m.			
1:15-4:15 p.m.	Oral Abstract Session	Head and Neck Cancer	S100a   Live Stream
3:39-3:51 p.m.	Abstract 6008: Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic thyroid cancer (BRAFM-ATC): A multicenter Phase II trial.		Mark Zafereo, M.D.
4:03-4:15 p.m.	Panel Question and Answer		
1:15-2:45 p.m.	Clinical Science Symposium	The Future Is Now: Innovations in Medical Education	E350   On Demand
	Chair		
2:27-2:45 p.m.	Panel Question and Answer Moderator		Nishin Bhadkamkar, M.D.
1:30-4:30 p.m.	Poster Sessions	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Lung Cancer—Non-Small Cell Metastatic Prevention, Risk Reduction, and Genetics Quality Care/Health Services Research	Hall A   On Demand
		<b>See the full listing of posters from MD Anderson starting on page 9.</b>	
2-2:30 p.m.	Meet the Experts: New horizons in lung cancer treatment Eric Singhi, M.D., Ferdinandos Skoulidis, M.D., Ph.D., and Natalie Vokes, M.D.		MD Anderson Booth 10059
3-4:30 p.m.	Rapid Oral Abstract Session	Central Nervous System Tumors	S102   On Demand
3:06-3:12 p.m.	Abstract 2013: Phase I study of HMPL-306, an inhibitor of mutant IDH1/IDH2 (mIDH1/2), in western patients (pts) with advanced mIDH solid tumor, including glioma.		Jordi Rodon Ahnert, M.D., Ph.D.
3:18-3:30 p.m.	Panel Question and Answer		
3-6 p.m.	Oral Abstract Session	Developmental Therapeutics—Immunotherapy	Hall D2   Live Stream
3:12-3:24 p.m.	Abstract 2501: First-in-human Phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors.		Timothy Yap, M.B.B.S, Ph.D.
3:48-4 p.m.	Panel Question and Answer		
3:15-3:45 p.m.	Meet the Experts: Training at MD Anderson: Investigational Cancer Therapeutics Fellowship Sarina Piha-Paul, M.D.		MD Anderson Booth 10059
4:45-6 p.m.	Education Session	Artificial Intelligence in the Clinic: Creating Harmony or Just Adding Noise?	S102   On Demand
	Chair		
4:45-5 p.m.	Can a Robot Write My Notes? Real-World Examples of Ambient Listening Technology		Katy French, M.D.
5:30-6 p.m.	Panel Question and Answer Moderator		

Sunday, June 1			
8-9:15 a.m.	Education Session	Proposed Federal and State Policy Changes to Oncology Reimbursement: A Tsunami or Just a Change in Tide?	E350   On Demand
	Chair		
8-8:15 a.m.	Site Neutrality: Curbing the Cost of Cancer Care, but at What Risk?		Kerin Adelson, M.D.
8:45-9:15 a.m.	Panel Question and Answer Moderator		
8-9:30 a.m.	Rapid Oral Abstract Session	Breast Cancer—Local/Regional/Adjuvant	Hall B1   Live Stream
8-8:06 a.m.	Abstract LBA509: NRG-BR003: A randomized Phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC.		Vicente Valero, M.D.
8:18-8:30 a.m.	Panel Question and Answer		
8-11 a.m.	Oral Abstract Session	Lung Cancer—Non-Small Cell Metastatic	Arie Crown Theater   Live Stream
	Chair		
8:48-9 a.m.	Panel Question and Answer Moderator		Natalie Vokes, M.D.
9:36-9:48 a.m.			
10:36-10:48 a.m.			
8:15-9:30 a.m.	Highlights of the Day Session	Highlights of the Day I	Hall D1   Live Stream
8:30-8:45 a.m.	Gastrointestinal Cancer—Colorectal and Anal		Christine Parseghian, M.D.
9 a.m.-12 p.m.	Poster Sessions	Care Delivery/Models of Care Gynecologic Cancer Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allograft Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia Hematologic Malignancies— Plasma Cell Dyscrasia Melanoma/Skin Cancers	Hall A   On Demand
See the full listing of posters from MD Anderson starting on page 9.			
9:45 a.m.-12:45 p.m.	Oral Abstract Session	Symptom Science and Palliative Care	S100bc   Live Stream
9:45-9:57 p.m.	Abstract LBA12000: PRO-ACTIVE: Results of a pragmatic Phase IV randomized trial comparing the effectiveness of prophylactic swallow intervention for patients receiving radiotherapy for head and neck cancer.		Katherine Hutcheson, Ph.D.
10:33-10:45 a.m.	Panel Question and Answer		
9:45 a.m.-12:45 p.m.	Oral Abstract Session	Sarcoma	S100a   Live Stream
	Chair		
10:33-10:45 a.m.	Panel Question and Answer Moderator		Elise Nassif Haddad, M.D., Ph.D.
11:33-11:45 a.m.			
12:09-12:21 p.m.	Abstract 11508: Spatial transcriptomic profiling from over 300 leiomyosarcoma samples.		Ryan Denu, M.D., Ph.D.
12:33-12:45 p.m.	Panel Question and Answer Moderator		Elise Nassif Haddad, M.D., Ph.D.
	Panel Question and Answer		Ryan Denu, M.D., Ph.D.
9:45 a.m.-12:45 p.m.	Oral Abstract Session	Genitourinary Cancer—Kidney and Bladder	Hall D2   Live Stream

12:09-12:21 p.m.	Absrtract 4508: ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Updated results from the Phase I TRAVERSE study.		Samer Srour, M.B.Ch.B.
12:33-12:45 p.m.	Panel Question and Answer		
10-10:30 a.m.	<b>Meet the Experts: The next era in colorectal cancer management</b> S. Daniel Haldar, M.D., and Scott Kopetz, M.D., Ph.D.		MD Anderson Booth 10059
12-12:30 pm.	<b>Meet the Experts: Emergent targeted therapies for high-risk B-cell malignancies</b> Krina Patel, M.D., Michael Wang, M.D., and Jason Westin, M.D.		
1-1:30 p.m.	<b>Meet the Experts: Innovative approaches to head and neck cancers</b> Neil Gross, M.D., and Katherine Hutcheson, Ph.D.		
2:15-2:45 p.m.	<b>Meet the Experts: Rare cancers: Defining the gold standard of care, Part II</b> Van Morris, M.D.		
3-3:30 p.m.	<b>Meet the Experts: Anaplastic thyroid: The evolving role of targeted therapies</b> Sarah Hamidi, M.D., Anastasios Maniakas, M.D., Ph.D., and Mark Zafereo, M.D.		
4:30-5:45 p.m.	Education Session	Capturing Unicorns: No Target Is Out of the Realm of Possibility	S100a   Live Stream
	Chair		
4:30-4:42 p.m.	Can We Target <i>MTAP</i> Deleted Tumors?		Jordi Rodon Ahnert, M.D., Ph.D.
5:18-5:45 p.m.	Panel Question and Answer Moderator		
4:30-5:45 p.m.	Education Session	Neo/Adjuvant Therapy for Soft Tissue Sarcoma: New Developments and Ongoing Unanswered Questions	S406   On Demand
	Chair		Vinod Ravi, M.D.
4:45-5 p.m.	Optimizing Regimens in the Neo/Adjuvant Setting for Localized Soft Tissue Sarcoma		Vinod Ravi, M.D.
5:15-5:45 p.m.	Panel Question and Answer Moderator		
4:30-6 p.m.	Rapid Oral Abstract Session	Genitourinary Cancer—Prostate, Testicular, and Penile	Hall D2   Live Stream
	Chair		
4:48-5 p.m.	Panel Question and Answer Moderator		Karen Hoffman, M.D.
5:18-5:30 p.m.			
5:48-6 p.m.			
4:30-6 p.m.	Rapid Oral Abstract Session	Quality Care/Health Services Research	S402   On Demand
5:30-5:36 p.m.	Abstract 11015: Overall survival and quality of life superiority in modern Phase III oncology trials.		Alexander Sherry, M.D.
5:48-6 p.m.	Panel Question and Answer		
4:30-6 p.m.	Clinical Science Symposium	Adjunctive Therapies in Colon Cancer—As Good as a Drug?	Hall B1   Live Stream
	Chair		Y. Nancy You, M.D.
5:42-6 p.m.	Panel Question and Answer Moderator		

Monday, June 2			
8:00-9:15 a.m.	Education Session	Speaking to Power with Power: Advocating for Your Profession	E350   On Demand
8:12-8:24 a.m.	Finding Your Voice: What You Say Matters		Jason Westin, M.D.
8:48-9:15 a.m.	Panel Question and Answer		
8-9:30 a.m.	Rapid Oral Abstract Session	Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology	S406   On Demand
8:30-8:36 a.m.	Abstract 3012: Preliminary results from a first-in-human, Phase I/II study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced solid tumors.		Ecaterina Dumbrava, M.D.
8:48-9 a.m.	Panel Question and Answer		
8-9:30 a.m.	Clinical Science Symposium	Diving Deeper to Inform Hereditary Cancer Risk and Outcomes	S103   On Demand
8:36-8:48 a.m.	Leveraging Genetics to Inform Breast Cancer Survival		Banu Arun, M.D.
9:12-9:30 a.m.	Panel Question and Answer		
8-9:30 a.m.	Rapid Oral Abstract Session	Hematologic Malignancies—Plasma Cell Dyscrasia	E450b   On Demand
9:12-9:18 a.m.	Abstract 7517: Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the Phase III IMROZ study.		Robert Orlowski, M.D., Ph.D.
9:18-9:30 a.m.	Panel Question and Answer		
8-11 a.m.	Oral Abstract Session Chair	Gynecologic Cancer	S100a   Live Stream
8:36-8:48 a.m.	Panel Question and Answer Moderator		Anuja Jhingran, M.D.
9:36-9:48 a.m.			
10:36-10:48 a.m.			
Meet the Experts: Accelerating drug discovery with AI Caroline Chung, M.D., and Timothy Heffernan, Ph.D.			MD Anderson Booth 10059
9-9:30 a.m.	Meet the Experts: Designing clinical trials for new targets, Part I Timothy Yap, M.B.B.S, Ph.D.		
9 a.m.-12 p.m.	Poster Session	Breast Cancer—Metastatic Breast Cancer— Local/Regional/Adjuvant Genitourinary Cancer—Kidney and Bladder Head and Neck Cancer	Hall A   On Demand
See the full listing of posters from MD Anderson starting on page 9.			
9:45-11 a.m.	Education Session	Multicancer Early Detection Testing: Are There Cures Without Costs?	S102   On Demand
9:45-10 a.m.	Multicancer Early Detection Research: Which Endpoints Will Justify Widespread Adoption?		Jennifer Litton, M.D.
10:30-11 a.m.	Panel Question and Answer		

9:45-11:15 a.m.	Rapid Oral Abstract Session	Melanoma/Skin Cancers	E451   On Demand
9:57-10:03 a.m.	Abstract 9511: Clinical outcomes of the DIET study: A randomized controlled Phase II trial of a high fiber diet intervention (HFDI) in patients with melanoma receiving immune checkpoint blockade (ICB).		Yufan Qiu, M.D., Ph.D.
10:03-10:15 a.m.	Panel Question and Answer		
9-9:30 a.m.	<b>Meet the Experts: The power of pathology</b> Lei Huo, M.D., Ph.D., and Lavinia Middleton, M.D.		<b>MD Anderson Booth 10059</b>
11:30 a.m.-12:45 p.m.	Education Session	Leveling Up: Harnessing Cutting-Edge Technology to Enhance Oncology Education and Learning	E350   On Demand
11:30-11:45 a.m.	Artificial Intelligence Empowering Cancer Knowledge: What's Here and What's Coming Soon		Caroline Chung, M.D.
12:15-12:45 p.m.	Panel Question and Answer		
11:30 a.m.-12:45 p.m.	Education Session	Bispecific and Multispecific Antibodies in Hemato-Oncology	S406   On Demand
12-12:15 p.m.	Bispecifics Plus Tyrosine Kinase Inhibition in Combination Strategy		Funda Meric-Bernstam, M.D.
12:15-12:45 p.m.	Panel Question and Answer		
11:30 a.m.-12:45 p.m.	Education Session	Changes in Upfront Therapy in Hematologic Malignancies	E450b   On Demand
11:45 a.m.-12 p.m.	Treatment Options for Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia		Elias Jabbour, M.D.
12:15-12:45 p.m.	Panel Question and Answer		
11:30 a.m.-2:30 p.m.	Oral Abstract Session	Prevention, Risk Reduction, and Genetics	100a   Live Stream
	Chair		Abenaa Brewster, M.D.
12:18-12:30 p.m.	Panel Question and Answer Moderator		
1:18-1:30 p.m.			
2:18-2:30 p.m.			
12-12:30 p.m.	<b>Meet the Experts: Metastatic melanoma and immunotherapy: What's next?</b> Rodabe Amaria, M.D., Elizabeth Burton, Ph.D., Jennifer McQuade, M.D., and Hussein Tawbi, M.D., Ph.D.		<b>MD Anderson Booth 10059</b>
1-1:30 p.m.	<b>Meet the Experts: The shifting gynecologic cancers landscape</b> Shannon Westin, M.D.		
1:15-2:30 p.m.	Education Session	Is Less More? Maximizing Outcomes by Tailoring Treatments to Patients: Oncofertility and Oncomenopause	S100bc   Live Stream
1:39-1:51 p.m.	State-of-the-Art Options for Fertility		Terri Lynn Woodard, M.D.
2:03-2:30 p.m.	Panel Question and Answer		
1:30-4:30 p.m.	Poster Session	Symptom Science and Palliative Care Developmental Therapeutics— Immunotherapy	Hall A   On Demand

		<b>Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology</b>	
<b>See the full listing of posters from MD Anderson starting on page 9.</b>			
<b>2:30-3 p.m.</b>	<b>Meet the Experts: New approaches to prostate cancer</b> Ana Aparicio, M.D., and Andrew Hahn, M.D.		<b>MD Anderson Booth 10059</b>
3-6 p.m.	Oral Abstract Session	Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allograft	S100a   Live Stream
3:24-3:36 p.m.	Abstract 6502: Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study.		Naveen Pemmaraju, M.D.
3:48-4 p.m.	Panel Question and Answer		Naveen Pemmaraju, M.D.
4-4:12 p.m.	Abstract 6503: Phase II study of cladribine, low-dose cytarabine, and venetoclax, alternating with azacitidine and venetoclax, in higher-risk chronic myelomonocytic leukemia and myelodysplastic syndromes.		Guillermo Montalban-Bravo, M.D.
5-5:12 p.m.	Panel Question and Answer		
<b>4:30-5 p.m.</b>	<b>Meet the Experts: New approaches to prostate cancer</b> Cathy Dumbrava, M.D., and David Hong, M.D.		<b>MD Anderson Booth 10059</b>
<b>Tuesday, June 3</b>			
8-9:30 a.m.	Rapid Oral Abstract Session	Gynecologic Cancer	S100bc   Live Stream
8:30-8:36 a.m.	Abstract 5512: Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA.		Shannon Westin, M.D.
8:48-9 a.m.	Panel Question and Answer		
8-9:15 a.m.	Highlights of the Day	Highlights of the Day II	Hall D1   Live Stream
8:45-9 a.m.	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers		Eric Singhi, M.D.
9:45 a.m.- 12:45 p.m.	Oral Abstract Session	Melanoma/Skin Cancers	S100a   Live Stream
11:21-11:33 a.m.	Discussant: Neoadjuvant Survivor: Who Stays on the Island?		Rodabe Amaria, M.D.
11:33-11:45 a.m.	Panel Question and Answer		
9:45 a.m.- 12:45 p.m.	Rapid Oral Abstract Session	Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allograft	S100bc   Live Stream
12:21-12:33 p.m.	Discussant: BCMA- CART, One Treatment, Two Diseases		Krina Patel, M.D.
12:33-12:45 p.m.	Panel Question and Answer		
9:45 a.m.- 12:45 p.m.	Oral Abstract Session	Genitourinary Cancer—Prostate, Testicular, and Penile	Hall D1   Live Stream
12:09-12:21 p.m.	Abstract 5008: C3NIRA: Randomized Phase II study of carboplatin-cabazitaxel-cetrelimab (anti-PD-1) induction followed by niraparib +/- cetrelimab maintenance in men with aggressive variant prostate cancers (AVPC).		Ana Aparicio, M.D.
12:33-12:45 p.m.	Panel Question and Answer		

Posters		Hall A   On Demand
Saturday, May 31   9 a.m.-12 p.m.		
Poster Board	Sarcoma	
59	Abstract 11576: NF1- and non-NF1-associated malignant peripheral nerve sheath tumors (MPNST): The University of Texas MD Anderson (MDACC) experience.	Prapassorn Thirasastr, M.D.
63b	Abstract TPS11583: Phase I/II study to evaluate the feasibility and efficacy of sequential abemaciclib and gemcitabine treatment in patients with retinoblastoma (Rb)-positive leiomyosarcoma (LMS) and dedifferentiated liposarcoma (DDLPS).	Elise Nassif Haddad, M.D., Ph.D.
Poster Board	Central Nervous System Tumors	
94	Abstract 2048: Effect of armed oncolytic adenovirus on immunotherapy for primary and metastatic brain tumors.	Jiasen He, MD
140b	Abstract TPS140b: Dual targeting of VEGF and PD-1: A Phase I/II trial of ivonescimab, a novel bispecific antibody, in recurrent glioblastoma.	Anuj Patel, M.D.
Poster Board	Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary	
345	Abstract 4055: Safety and efficacy of endoscopic treatment with mucosal resection, radiofrequency ablation, and cryotherapy in the curative treatment of early esophageal squamous cell cancer and dysplasia.	Sidra Naz, M.D.
381	Abstract 4091: Multimodal evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD)-related biliary tract cancer (BTC) and immunotherapy outcomes.	Nakul Manish Shah, M.D.
401	Abstract 4111: Association of gut microbiota with therapy efficacy and prognosis in biliary tract cancer.	Fen Saj, M.D., M.B.B.S.
435	Abstract 4145: A Phase II study of lenvatinib plus everolimus in advanced extra-pancreatic neuroendocrine tumors (epNETs): Updated results and real-world comparison.	Guglielmo Vetere, M.D.
442	Abstract 4152: A Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer.	Daniel Haldar, M.D.
443	Abstract 4153: Pancreatic adenosquamous carcinoma (PASC): A comparative genomic landscape study.	
469	Abstract 4179: Clinical outcomes and molecular characteristics of patients with metastatic pancreatic ductal adenocarcinoma according to involved metastatic sites.	Mahmoud Yousef, M.D.
488	Abstract 4198: Uncovering the tumor microenvironment (TME): Exploring survival and immunotherapy (IO) response in cancer of unknown primary (CUP).	Joelle Allam, M.D.
493b	Abstract TPS4206: A randomized, double-blinded, international Phase III trial comparing HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy with or without pembrolizumab for first-line treatment for HER2-positive locally advanced or metastatic G/GEJ cancer.	Jaffer Ajani, M.D.
495b	Abstract 4210: A Phase II study of perioperative intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology.	Brian Badgwell, M.D.
Poster Board	Gastrointestinal Cancer—Colorectal and Anal	
203	Abstract 3534: Open-label Phase Ib/II study of cetuximab (CET) plus LY3214996 with or without abemaciclib in patients (pts) with anti-EGFR-refractory metastatic colorectal cancer (mCRC).	Guglielmo Vetere, M.D.
205	Abstract 3536: Survival of patients (pts) with microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal carcinoma (mCRC) treated with EO4010 + nivolumab (EO/N).	Arvind Dasari, M.D.
227	Abstract 3558: Colorectal cancer with gene fusions: Navigating the genomic landscape and treatment selection in a Phase I unit.	Camila Braganca Xavier, M.D.

242	Abstract 3573: Clinicopathologic features of complement activation signatures in colorectal cancer.	Mir Lim, M.D.
260	Abstract 3591: Biologic correlates of circulating tumor DNA (ctDNA) shedding in the INTERCEPT colorectal cancer (CRC) study.	Emerik Oesterlund, M.D., Ph.D.
307b	Abstract TPS3644: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.	Arvind Dasari, M.D.
<b>Saturday, May 31   1:30-4:30 p.m.</b>		
Poster Board	Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers	
167	Abstract 8046: Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2.	Tina Cascone, M.D., Ph.D.
209	Abstract 8088: Real-world efficacy and safety of tarlatamab in patients with relapsed extensive-stage small cell lung cancer.	Mitchell Parma, M.D.
232	Abstract 8111: Association of immune-related adverse events with survival and treatment outcomes in thymic tumors treated with immune checkpoint inhibitors.	Harold Nathan Tan, M.D.
Poster Board	Prevention, Risk Reduction, and Genetics	
310	Abstract 10585: Clinical features and occurrence of other cancers in patients with chronic lymphocytic leukemia and their families with POT1 tumor predisposition syndrome.	Jennifer Croden, M.D.
318	Abstract 10593: Results of a program addressing multi-level barriers to completion of hereditary cancer genetic testing (GT) among underserved and minority individuals in Texas.	Darya Aleksandrovna Kizub, M.D.
334	Abstract 10609: Clinical characteristics and cancer spectrum among breast cancer patients with TP53 germline mutation from a single institution.	Ashley Woodson
347	Abstract 347: Characteristics and outcome of breast cancers diagnosed in patients with germline ATM mutations.	Amanda Lanier
Poster Board	Quality Care/Health Services Research	
357	Abstract 11018: Improving clinical trial interpretability and efficiency: A Bayesian re-analysis of individual patient outcomes from 230 Phase III oncology trials.	Alexander Sherry, M.D.
410	Abstract 11071: Patient-reported communication and satisfaction in breast cancer: Does doctor-patient identity concordance matter?	Kamaria Lee, M.D.
418	Abstract 11079: Shifts in Medicare spending for patients with cancer undergoing chemotherapy following implementation of the Maryland Global Budget Revenue program.	Yu-Li Lin
427	Abstract 11088: United States treatment pattern response to carboplatin and cisplatin shortages.	John Kent Lin, M.D.
476	Abstract 11137: Improving genetic counseling uptake for breast, pancreatic, and prostate cancers at a safety net hospital.	Jenny Jing Xiang, M.D.
Poster Board	Lung Cancer—Non-Small Cell Metastatic	
47	Abstract 8567: Race-associated clinicogenomic correlates of outcomes to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer (NSCLC).	Nirosha Perera, M.D.
115	Abstract 8635: Therapeutic responses in 555 advanced NSCLC patients enrolled in Phase I studies at MD Anderson Cancer Center.	Jeong Uk Lim, M.D., Ph.D.
120	Abstract 8640: Vabametakib in MET exon 14 skipping non-small-cell lung cancer: Efficacy and safety from the open-label, Phase II, cohort-1 trial.	Xiuning Le, M.D., Ph.D.
127b	Abstract TPS8648: SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with <i>HER2</i> -activating mutations.	
131b	Abstract TPS8656: Krascendo 2: A Phase III study of divarasisib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously	Ferdinandos Skoulidis, M.D., Ph.D.

	untreated, advanced or metastatic, <i>KRAS</i> G12C-mutated non-small cell lung cancer (NSCLC).	
135a	Abstract TPS863: A Phase I/II open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of BH-30643 in adult subjects with locally advanced or metastatic NSCLC harboring EGFR and/or HER2 mutations (SOLARA)	Xiuning Le, M.D., Ph.D
135b	Abstract TPS864: A randomized Phase III study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non-small cell lung cancer: HARMONI-3.	Jianjun Zhang, M.D., Ph.D.
136a	Abstract TPS8665: NVL-330, a selective HER2 tyrosine kinase inhibitor, in patients with advanced or metastatic HER2-altered non-small cell lung cancer: The Phase I HEROEX-1 study.	Xiuning Le, M.D., Ph.D.
137a	Abstract TPS8667: A Phase II safety and efficacy study of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic solid tumors and a <i>SMARCA4</i> mutation.	Timothy Yap, M.B.B.S., Ph.D.
<b>Sunday, June 1   9 a.m.-12 p.m.   Hall A   On Demand</b>		
Poster Board	Melanoma/Skin Cancers	
2	Abstract 9519: OBX-115 engineered tumor-infiltrating lymphocytes (TIL) with regulatable membrane-bound IL15 (mbIL15): Translational data from a single-center Phase I trial in patients (pts) with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.	Rodabe Amaria, M.D.
4	Abstract 9521: Association of KIT mutations with risk of central nervous system (CNS) metastasis (met) in patients (pts) with mucosal melanoma (MM).	Afsaneh Amouzegar, M.D.
8	Abstract 9525: RELATIVITY-020: Intracranial (IC) activity of nivolumab + relatlimab (NIVO + RELA) in patients (pts) with PD-(L)1 refractory melanoma with melanoma brain metastases (MBM).	Hussein Tawbi, M.D., Ph.D.
35	Abstract 9552: Nautilus, a Phase Ib/II trial of combining oral HDAC inhibitor (HDACi) with MEK inhibitor (MEKi) in patients with NRAS-mutated metastatic melanoma (MM).	Rodabe Amaria, M.D.
39	Abstract 9556: Phase I dose escalation trial of STX-001, an LNP-encapsulated self-replicating mRNA expressing IL-12, in patients (pts) with advanced solid tumors.	Sarina Piha-Paul, M.D.
44	Abstract 9561: Delineating the role of the microbiome and tumor microenvironment interactions driving mucosal melanoma (MM) response and resistance to immune checkpoint inhibitor (ICI) treatment.	Florentia Dimitriou, M.D., Ph.D.
75a	Abstract TPS9592: Phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (N) and relatlimab (R) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).	Isabella Glitza, M.D., Ph.D.
75b	Abstract TPS9593: Phase I/IIa dose finding study of triplet regimen of relatlimab (RELA), ipilimumab (IPI), and nivolumab (NIVO) in first-line therapy of metastatic melanoma (TRINITY).	Elizabeth Burton, Ph.D.
77a	Abstract TPS9596: A randomized Phase II peri-operative (neoadjuvant plus adjuvant) study of fianlimab (anti-LAG-3) plus cemiplimab (anti-PD-1) versus anti-PD-1 alone in patients with resectable stage III and IV melanoma.	Rodabe Amaria, M.D.
80a	Abstract TPS9602: Phase I dose escalation and expansion study of PRAME T-cell receptor (TCR) engineered IL15-transduced cord blood-derived natural killer (NK) cells in patients with recurrent and/or refractory melanoma (PRAMETIME-Mel).	Derrick Tao, M.D.
Poster Board	Hematologic Malignancies—Plasma Cell Dyscrasia	
119	Abstract 7551: Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis.	Robert Orłowski, M.D., Ph.D.

131a	Abstract TPS7563: QUINTESSENTIAL: A multicenter Phase II study evaluating the efficacy and safety of arlocabtagene autoleucl (arlo-cel) in triple- and quad-class exposed patients with relapsed or refractory multiple myeloma (RRMM).	Krina Patel, M.D.
Poster Board	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant	
147	Abstract 6531: Subgroup analysis by fitness criteria of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with first-line (1L) tagraxofusp (TAG).	Naveen Pemmaraju, M.D.
155	Abstract 6539: Cytomolecular mechanisms of relapse after frontline FLT3 inhibitor (FLT3i)-based therapy in FLT3-mutated (mut) acute myeloid leukemia (AML).	Sankalp Arora, M.B.B.S.
159	Abstract 6543: Brexucabtagene autoleucl (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemia.	Niranjan Khaire, M.B.B.S., M.D., D.M.
160	Abstract 6544: Impact of TP53 mutations and variant allelic frequency on survival in adults with newly diagnosed acute lymphoblastic leukemia.	Roberta Azevedo, M.D.
165	Abstract 6549: Outcomes of therapy-related AML (T-AML) with venetoclax-based therapies.	Jennifer Croden, M.D.
167	Abstract 6551: Phase II trial of 10-day ASTX727 (decitabine/cedazuridine) in combination with venetoclax for relapsed or refractory acute myeloid leukemia.	Mehmet Uyanik, M.D.
177	Abstract 6561: Myeloablative fractionated busulfan conditioning regimen with sorafenib for allogeneic stem cell transplant in AML: Results of a Phase I/II study.	Uday Popat, M.D.
181	Abstract 6565: Early predictors of treatment-free remission in chronic myeloid leukemia.	Aziz Farhat, M.D.
182	Abstract 6566: Long-term follow-up of treatment-free remission in chronic myeloid leukemia after discontinuation of tyrosine kinase inhibitor therapy.	Mehmet Uyanik, M.D.
183	Abstract 6567: Allogeneic stem cell transplantation-related outcomes in myelodysplastic syndromes.	Alexandre Bazinet, M.D.
196b	Abstract TPS6581: First-in-human study of autologous chimeric engulfment receptor T-cell CER-1236 targeting TIM-4-I in acute myeloid leukemia (CertainT-1).	Abhishek Maiti, M.D., M.B.B.S.
197b	Abstract TPS6583: A Phase II open-label study of olutasidenib post-transplant maintenance therapy for patients with IDH1-mutated myeloid malignancies.	Jeremy Ramdial, M.D.
198a	Abstract TPS6585: Phase II study evaluating olutasidenib in patients with IDH1-mutated clonal cytopenia of undetermined significance or lower-risk myelodysplastic syndromes/chronic myelomonocytic leukemia.	Kelly Chien, M.D.
199a	Abstract TPS6586: Phase II study evaluating olutasidenib and azacitidine in patients with <i>IDH1</i> -mutated higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or advanced myeloproliferative neoplasms.	
Poster Board	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	
206	Abstract 7023: Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucl (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL).	Fateeha Furqan, M.D.
219	Abstract 7036: Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the Phase II CAPTIVATE study.	William Wierda, M.D., Ph.D.
220	Abstract 7037: Propensity score (PS) comparison between lisocabtagene maraleucl (liso-cel) plus ibrutinib combination therapy (combo) and liso-cel monotherapy (mono) cohorts from TRANSCEND CLL.	
222	Abstract 7039: Comparison of outcomes for patients (pts) with R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton tyrosine kinase inhibitor (BTKi) and venetoclax from the TRANSCEND CLL 004 study versus a matched cohort of real-world (RW) pts.	William Wierda, M.D., Ph.D.

228	Abstract 7045: Survival outcomes of Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified: Results from Latin American and United States cohorts.	Jose Concepcion-Holguin, M.D.
260	Abstract 7077: Frontline brentuximab vedotin (BV) and CHP in patients (pts) with peripheral T-cell lymphoma (PTCL) with <10% CD30 expression: Primary analysis results from the Phase II SGN35-032 study.	Swaminathan Iyer, M.D.
267a	Abstract TPS7085: ALPHA3: A pivotal Phase II study of first-line (1L) consolidation with cemacabtagene anesgedleucel (cema-cel) in patients (pts) with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy.	Jason Westin, M.D.
267b	Abstract TPS7086: A Phase II study to confirm safety and efficacy of MB-105, an autologous CD5-directed CAR T-cell therapy, in relapsed/refractory T-cell lymphoma (R/R TCL).	Swaminathan Iyer, M.D.
273a	Abstract 7097: A Phase I trial of BTM-3566 in relapsed/refractory mature B cell lymphomas.	Michael Wang, M.D.
Poster Board	Care Delivery/Models of Care	
291	Abstract 1538: OP-35: Does a tool designed to measure potentially preventable chemotherapy toxicities do so effectively?	Ryan Huey, M.D.
Poster Board	Gynecologic Cancer	
460	Abstract 5562: Phase I study of sustained and local delivery of intraperitoneal IL-2 using encapsulated cells in patients with platinum-resistant high-grade serous carcinoma.	Amir Jazaeri, M.D.
471	Abstract 5573: EON: Phase II trial of etigilimab (MPH313) in combination with nivolumab in patients with recurrent platinum-resistant clear cell ovarian cancer.	Ji Son, M.D.
502	Abstract 5604: Clinicopathological features and survival outcomes in women with endometrial neuroendocrine tumors.	Morgan Bou Zerdan, M.D.
<b>Monday, June 2   9 a.m.-12 p.m.   Hall A   On Demand</b>		
Poster Board	Breast Cancer—Metastatic	
16	Abstract 1037: Characterization of the immune microenvironment and spatial phenotypes across HER2 subtypes in advanced or metastatic breast cancer.	Ayse Koksoy, Ph.D.
28	Abstract 1049: Macroscale genomic alterations in histomolecular invasive lobular carcinoma compared to other breast cancer subtypes.	Jason Mouabbi, M.D.
90	Abstract 1111: Geographic access to triple negative breast cancer (TNBC) clinical trials: Are trials located near Black women?	Mariana Chavez Mac Gregor, M.D.
101a	Abstract TPS1124: LITESPARK-029: A Phase II, randomized, open-label study of belzutifan plus fulvestrant in participants with estrogen receptor-positive, HER2-negative unresectable locally advanced or metastatic breast cancer after progression on previous endocrine therapy.	Bora Lim, M.D.
Poster Board	Breast Cancer—Local/Regional/Adjuvant	
118	Abstract 525: Chemotherapy (CT) declination among patients with early-stage hormone receptor positive breast cancer (BC) and high Oncotype DX recurrence scores (RS).	Inimfon Jackson, M.D., Ph.D.
121	Abstract 528: Real-world patterns of Oncotype DX (O-Dx) testing and chemotherapy (CT) use among patients with early-stage, hormone receptor-positive (HR+) breast cancer (BC).	Marija Sullivan, M.D.
173	Abstract 580: Implications for sentinel lymph node biopsy (SLNB) omission in patients with early-stage node-negative HR+/HER2- breast cancer undergoing mastectomy.	Jennifer Hechao Chen, M.D.
185	Abstract 592: Early on-treatment (on-Rx) tumor volume reduction (TVR) to predict response to the KEYNOTE-522 (KN-522) regimen in early stage triple negative breast cancer (TNBC).	Lei Huo, M.D., Ph.D.

196	Abstract 603: Outcomes of neoadjuvant endocrine therapy (NAET) versus neoadjuvant chemotherapy (NAC) in stage II-III invasive lobular carcinoma (ILC).	Jason Mouabbi, M.D.
Poster Board	Genitourinary Cancer—Kidney and Bladder	
366	Abstract 4566: Targeting the TGFβ signaling pathway to mitigate tumor metastasis in 9p21-loss urothelial bladder cancer.	Cindy Jiang, M.D.
411a	Abstract TPS4611: STARLITE-1: Phase Ib/II study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.	Eric Jonasch, M.D.
Poster Board	Head and Neck Cancer	
441	Abstract 6033: Initial safety and efficacy of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in combination with pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC.	Maura Gillison, M.D., Ph.D.
516	Abstract 6108: Outcomes with 177 lutetium-dotatate (177Lu-dotatate) in olfactory neuroblastoma (ONB): A case series.	Mateus Trinconi Cunha, M.D.
519a	Abstract TPS6113: A multicenter, randomized, double-blind, Phase II/III study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: The FORTIFI-HN01 study.	Renata Ferrarotto, M.D.
523b	Abstract TPS6122: A Phase III randomized study of ASP-1929 photoimmunotherapy in combination with pembrolizumab versus standard of care in locoregional recurrent head and neck squamous cell carcinoma (HNSCC).	Anastasios Maniakas, M.D., Ph.D.
<b>Monday, June 2   1 p.m.-4:30 p.m.   Hall A   On Demand</b>		
Poster Board	Symptom Science and Palliative Care	
130	Abstract 12110: Systematic screening of perception of curability among patients with advanced cancer: A longitudinal analysis.	Kayley Ancy, M.D.
154	Abstract 12134: Interrogating the interleukin-6 (IL-6)/IL-23/T-helper (Th)17 axis in immunotherapy toxicity: Mechanistic insights and therapeutic implications.	Noha Abdel-Wahab, M.D., Ph.D.
Poster Board	Developmental Therapeutics—Immunotherapy	
168	Abstract 2521: Phase I/II, open-label, first-in-human study of the anti-GPC3 T-cell engager SAR444200 in patients with advanced solid tumors: Updated efficacy and biomarker analysis.	Ecaterina Dumbrava, M.D.
185	Abstract 2538: Engineering iPSC-derived mesenchymal stem cells (i MSCs) to secrete IL-7/IL-15 for modulation of the tumor microenvironment in a "cold" ovarian tumor model.	Sandeep Singh, Ph.D.
219	Abstract 2572: Initial safety and efficacy results from a first-in-human, phase 1/2 study of SAR445877, an anti-PD-1/IL-15 fusion protein, for patients with advanced solid tumors.	Aung Naing, M.D.
265	Abstract 2618: Effect of AdAPT-001 on checkpoint inhibitor resistance in solid tumors.	Anthony Conley, M.D.
284	Abstract 2637: The predictive role of TRAIL gene expression in immune checkpoint inhibitor (ICI)-treated patients (pts).	Obada Ababneh, M.D.
307	Abstract 2660: Clinical outcomes of patients with or without DNA repair pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study.	Jacopo Venturini, M.D.
316a	Abstract TPS2670: A Phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001, a tetraspecific T cell engager-expander in patients with advanced solid tumors.	Ecaterina Dumbrava, M.D.
318b	Abstract TPS2625: A Phase I/II study of KSQ-004EX: Autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and Regnase-1, in patients with select advanced solid tumors.	Rodabe Amaria, M.D.

320b	Abstract TPS2679: Safety and efficacy of HLA-G–targeted CAR T cells (IVS-3001) in patients with advanced HLA-G–positive solid tumors: Clinical trial in progress.	Samer Srour, M.B.Ch.B.
324a	Abstract TPS2686: A Phase Ia/Ib study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of IMGS-001 in patients with relapsed or refractory advanced solid tumors.	David Hong, M.D.
Poster Board	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	
353	Abstract 3038: Precectabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer (mCRC): Results from the dose optimization of the Phase I PROCEADE CRC-01 study.	Scott Kopetz, M.D., Ph.D.
363	Abstract 3048: Development of a methylation-based, tissue-free test for the detection of molecular residual disease by circulating tumor DNA.	John Paul Shen, M.D.
387	Abstract 3072: Clinical utility of comprehensive transcriptome testing in advanced solid tumors.	Fei Su, Ph.D.
398	Abstract 3083: The first-in-human Phase I/II study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors.	Siqing Fu, M.D., Ph.D.
401	Abstract 3086: EphA2 siRNA in DOPC nanoliposomes (EPHARNA): A Phase I clinical trial in patients with solid tumors.	Ravali Annam Reddy, M.D.
415	Abstract 3100: SPYK04, a novel RAF-MEK molecular glue: Dose escalation (DE) in first-in-human study for MAPK pathway-altered solid tumors.	Sarina Piha-Paul, M.D.
439	Abstract 3124: Phase I study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors: Results on safety, pharmacokinetics, and anti-tumor activity.	Apostolia Tsimberidou, M.D., Ph.D.